208
Participants
Start Date
March 1, 2025
Primary Completion Date
August 1, 2026
Study Completion Date
August 1, 2027
Serplulimab
IV 3 mg/kg on Day 1, q2w
Chemotherapy
"Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours"
SABR
SABR: 25-60 Gy/5 Fx
Targeted therapy
Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly ; Bevacizumab: 5 mg/kg IV on Day 1
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
Huai'an Second People's Hospital, Huaian
NOT_YET_RECRUITING
Qianfoshan Hospital of Shandong Province, Jinan
NOT_YET_RECRUITING
Taian City Central Hospital, Taian
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Anyang Cancer Hospital, Anyang
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
NOT_YET_RECRUITING
Lanzhou Military Region General Hospital, Lanzhou
Fudan University
OTHER